News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Re-engineered neural stem cells use a bystander effect to target glioma

Posted on: 08/08/2005

Re-engineered neural stem cells use a bystander effect to target glioma

Gene Therapy Weekly via NewsEdge Corporation :.
2005 AUG 4 - ( -- Re-engineered neural stem cells use a bystander effect to target glioma.

"Since neural stem cells (NSCs) have the ability to migrate toward a tumor mass, genetically engineered NSCs were used for the treatment of gliomas. We first evaluated the 'bystander effect' between NSCs transduced with the herpes simplex virus-thymidine kinase (HSVtk) gene (NSCtk) and C6 rat glioma cells under both in vitro and in vivo conditions," researchers in Japan report.

"A potent bystander effect was observed in co-culture experiments of NSCtk and C6 cells. In the intracranial co-implantation experiments in athymic nude mice and Sprague-Dawley rats, the animals co-implanted with NSCtk and C6 cells and treated with ganciclovir (GCV) showed no intracranial tumors and survived more than 100 days, while those treated with physiological saline (PS) died of tumor progression," stated S. Li and colleagues, Hamamatsu University of School of Medicine.

"We next injected NSCtk cells into the pre-existing C6 tumor in rats and treated them with GCV or PS. The tumor volume was serially measured by magnetic resonance imaging. The tumor disappeared in six out of nine rats in the NSCtk/GCV group, while all the rats treated with PS died of tumor progression by day 21.

"The results indicate the feasibility of a novel gene therapy strategy for gliomas through a bystander effect generated by intratumoral injection of NSCtk cells and systemic GCV administration," researchers wrote.

Li and colleagues published their study in Cancer Gene Therapy (Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther, 2005;12(7):600-7).

For additional information, contact S. Li, Dept. of Neurosurgery, Hamamatsu University School of Medicine, Handayama, Japan.

Publisher contact information for the journal Cancer Gene Therapy is: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England.

Keywords: Handayama, Japan, Biotechnology, Cancer Gene Therapy, Genetic Engineering, Genetics, Neurology, Oncology, Glioma.
This article was prepared by Gene Therapy Weekly editors from staff and other reports. Copyright 2005, Gene Therapy Weekly via <>.

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557